Lipid profile during pregnancy in HIV-infected women

6533b837fe1ef96bd12a338b

RESEARCH PRODUCT

Lipid profile during pregnancy in HIV-infected women

M Floridia E Tamburrini M Ravizza C Tibaldi M F Ravagni Probizer G Anzidei M Sansone F Mori E Rubino M Meli S Dalzero G Guaraldi Italian Grp Surveillance Antiretro M Lanari B Guerra

subject

HIV Infections Triglyceride chemistry.chemical_compound Pregnancy Hiv infected Hyperlipidemia HIV Infection Pharmacology (medical)Pregnancy Complications Infectious triglycerides medicine.diagnostic_test Stavudine Stavudine Hyperlipidemia Infectious Diseases Treatment Outcome Italy Population Surveillance Population study lipids (amino acids peptides and proteins)Female Pregnancy Trimester Pregnancy Trimesters pregnancy Human medicine.drug Adult medicine.medical_specialty Logistic Model protease inhibitors Hyperlipidemias cholesterol; HIV; pregnancy; protease inhibitors; triglycerides protease inhibitor Internal medicine medicine Humans HIV Protease Inhibitor Triglycerides Pregnancy Triglyceride Cholesterol business.industry Cholesterol HDL cholesterol HIV Cholesterol LDL HIV Protease Inhibitors medicine.disease Lipid Metabolism Endocrinology Logistic Models chemistry Pregnancy Complications Infectiou HIV-1 Lipid profile business

description

Purpose: We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study. Method: Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal changes and differences in lipid values at each trimester by protease inhibitors (Pls) and stavudine use. Multivariate analyses were used to control for simultaneous factors potentially leading to hyperlipidemia. Study population included 248 women. Results: Lipid values increased progressively and significantly during pregnancy: mean increases between the first and third trimesters were 141.6 mg/dL for triglycerides (p <.001), 60.8 mg/dL for total cholesterol (p <.001), 13.7 mg/dL for HDL cholesterol (p <.001), and 17.8 mg/dL for LDL cholesterol (p =.001). At all trimesters, women on PIs had significantly higher triglyceride values compared to women not on Pis. The effect of Pls on cholesterol levels was less consistent. Stavudine showed a dyslipidemic effect at first trimester only. Multivariate analyses confirmed these observations and suggested a potential role of other cofactors in the development of hyperlipidemia during pregnancy. Conclusion: The changes observed point to the need to further explore the causes and the clinical correlates of hyperlipidemia during pregnancy in women with HIV.

year	journal	country	edition	language
2006-01-01

10.1310/hct0704-184 https://hdl.handle.net/11380/305151